Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 16/20 | 0.58 |
| ▸ | ITGA4 | P13612 | 16/20 | 0.58 |
| ▸ | ITGB7 | P26010 | 16/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27504636 | 1.00 | ITGB1 (0.58) | ITGB1ITGA4ITGB7ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL6292502 | 0.99 | ITGB1 (0.57) | ITGB1ITGA4ITGB7ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL6237763 | 0.99 | ITGB1 (0.57) | ITGB1ITGA4ITGB7ALDH1A1PTGS2 | |
| SCHEMBL22982364 | 0.88 | ITGB1 (0.63) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6297453 | 0.88 | ITGB1 (0.63) | ITGB1ITGA4ITGB7 | |
| SCHEMBL22996698 | 0.88 | ITGB1 (0.45) | ITGB1ITGA4ITGB7ALDH1A1PTGS2 | |
| SCHEMBL22996662 | 0.87 | ITGB1 (0.45) | ITGB1ITGA4ITGB7ALDH1A1PTGS2 | |
| SCHEMBL22996759 | 0.86 | ITGB1 (0.43) | ITGB1ITGA4ITGB7ALDH1A1PTGS2 | |
| SCHEMBL27486748 | 0.83 | ITGA4 (0.57) | ITGB1ITGA4ITGB7ALDH1A1 | |
| SCHEMBL6239532 | 0.83 | ITGA4 (0.57) | ITGB1ITGA4ITGB7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | GILEAD SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | GILEAD SCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4013499-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210053967-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021030438-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | GILEAD SCIENCES, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| US-6916933-B2 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMAN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1244625-B1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | HOFFMANN LA ROCHE (CH) | 2005-06-15 | — | — | EP | disclosed |
| CN-1196682-C | 4-pyridyl-N-acyl-L-phenylalanine | HOFFMANN LA ROCHE (CH) | 2005-04-13 | — | — | CN | disclosed |
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | KAPLAN GERALD LEWIS (US) | 2004-07-01 | — | — | US | disclosed |
| CN-1402709-A | 4-pyridinyl-N-acyl-L-phenylalanines | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | CN | disclosed |
| EP-1244625-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | KAPLAN GERALD LEWIS (US) | 2002-09-19 | — | — | US | disclosed |
| US-6388084-B1 | 4-pyridinyl-n-acyl-l-phenylalanines | HOFFMANN-LA ROCHE INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2001042215-A1 | 4-PYRIDINYL-N-ACYL-L-PHENYLALANINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127706-A1 | 4-Pyridinyl-n-acyl-l-phenylalanines | VCAM1, ICAM1, SELPLG | ITGB1 13/4885ITGA4 8/4885ITGB7 99/4885 |
| US-11578069-B2 | Compounds for inhibition of α4 β7 integrin | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-20210053967-A1 | COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN | ITGB7, ITGB4, ITGA4 | ITGB1 4/4885ITGA4 3/4885ITGB7 1/4885 |
| US-20020133015-A1 | 4-pyridinyl-N-acyl-L-phenylalanines | VCAM1, ICAM1, SELPLG | ITGB1 13/4885ITGA4 8/4885ITGB7 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.